J Phys Ther Rehabil | Volume 1, Issue 1 | Case Report | Open Access

Remission of Dermatomyositis Following Antitumor Combination Therapy in EBV-Associated Nasopharyngeal Carcinoma

Mingfen Chen^1,2#, Jun Long3^#*, Yian Wang⁴, Yuxuan Guo⁴, Xianjie Jiang⁵, Boshu Zheng², Rong Wang² and Jie Wang^2*

¹Department of Radiation Oncology, The Second Affiliated Hospital of Fujian Medical University, Fujian Medical University, China ²Department of Pathology and Institute of Oncology, The School of Basic Medical Sciences & Diagnostic Pathology Center, Fujian Medical University, China ³Shenzhen Key Laboratory of Energy Electrocatalytic Materials, Shenzhen Key Laboratory of Polymer Science and Technology, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, College of Materials Science and Engineering, Shenzhen University, China ⁴The Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, School of Medicine, Hunan Normal University; The Engineering Research Center of Reproduction and Translational Medicine of Hunan Province, China ⁵Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, China

^*Correspondance to: Jie Wang 

Abstract

Dermatomyositis, a rare autoimmune disorder that can act as a paraneoplastic syndrome associated with cancers, was observed in a patient with EBV-associated non-keratinizing nasopharyngeal carcinoma (stage IVa, cT3N2M0, EGFR positive). The patient underwent gemcitabine plus cisplatin induction chemotherapy, followed by intensity-modulated radiotherapy with concurrent Nimotuzumab targeted therapy and cisplatin. This treatment regimen successfully resolved both the nasopharyngeal carcinoma and the dermatomyositis.

Keywords:

#

Citation:

Chen M, Long J, Wang Y, Guo Y, Jiang X, Zheng B, et al. Remission of Dermatomyositis Following Antitumor Combination Therapy in EBV-Associated Nasopharyngeal Carcinoma. J Phys Ther Rehabil. 2024; 1(1): 1004..